SRDX - SurModics - Biotech IPO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SRDX - SurModics - Biotech IPO

SRDX 31.15

+5.7%

Apr 28 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lance Bredvold	6/25/2023 9:41:30 AM
	of 83

And now I'm full of SRDX common having bought significant amounts right around $30 on the assumption that the price will increase to $40. Also $35 puts sold for Nov expiration and net cost of less than $30. The 150 week moving average is still at $41 after a year of weak prices and I don't really expect more than almost breakeven EPS for 2023 after the ABT progress payment of $27mm. Revenues will not grow much during this year as ABT will be just starting their efforts with SurVeil and POUNCE along with currently marketed drug coated stents seem to grow sales at only a few percent at this point. I'm hopeful it will look like a small profit in 2024 with lots of potential on the small share base (<15mm last I checked). I'm not counting on much more than $40 though the stock has always been surprisingly buoyant to me. Getting as high as $82 in 2018 was just plain nutty.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next